A Spanish study revealed that patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) suffer more often from sexual dysfunction compared with a healthy population. Older age, unemployment, and lower income are all risk factors.
Data from a cross-sectional, observational study suggests patients with PsA were at 8 times greater risk of sexual dysfunction, and patients with RA were at 10 times greater risk when compared with their healthy counterparts .
Although previous studies hinted at a higher frequency of sexual dysfunction in RA and PsA, most were of low quality regarding the study design. “Most studies lack a control group,” said Dr Carlos Valera-Ribera (Doctor Peset University Hospital, Spain). Therefore, he and his team performed a study in which patients diagnosed with PsA and RA were compared with a control group of healthy individuals. Included were 188 adult patients of any sexual orientation in 2 different university hospitals. The researchers collected different variables, including age, sex, year of diagnosis, perceived health, marital status, level of education, income, history of depression, and treatment for mental health disease. All participants completed the 14-item Changes in Sexual Functioning Questionnaire (CSFQ-14), a standardised questionnaire used to evaluate changes in sexual function due to disease or medication in 4 different domains: pleasure, desire, arousal, and orgasm. A regression model was created to estimate the influence of the collected variables on the obtained results.
Of the 188 participants (52.7% women), 72 had a diagnosis of PsA and 27 of RA. They were compared with 89 healthy individuals matched by age (mean 48 ± 12.5 years). More than half of the participants assessed their own health as “good” or “very good”. Interestingly, 77.7% had a personal history of depression, which did not correlate significantly with sexual dysfunction. In contrast, older age, unemployment, and low income were factors associated with the risk of sexual dysfunction, consistent with earlier findings from studies including patients with rheumatic diseases. “All the domains of the sexual sphere were functionally deteriorated,” Dr Valera-Ribera said.
Around 80% of the participants were in a relationship. Nearly half of patients with RA (48.2%) experienced sexual dysfunction compared with 30.4% in the PsA group and only 5.9% in the control group. All the domains of the CSFQ-14 questionnaire were negatively affected by being diagnosed with PsA or RA (P<0.001). In general, men were more severely affected. The odds ratio of sexual dysfunction was 8.7 times higher in PsA patients and 10 times higher in RA patients.
Dr Valera-Ribera concluded that sexual health must be considered a holistic part of care. The CSFQ-14 is a valuable tool for the management of sexual health in people with inflammatory rheumatic diseases.
- Valera-Ribera C, et al. Impact of chronic joint diseases on the sexual sphere with regard to a healthy population: a multicenter study. OP0139, EULAR 2022 Congress, 1–4 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
« Comorbid depression comes with a profoundly higher mortality risk in RA Next Article
A novel oral treatment possibility for non-radiographic axSpA on the horizon »
Table of Contents: EULAR 2022
Letter from the Editor
EULAR 2022 Highlights Podcast
Late-Breaking Oral Abstracts
TYK2 inhibition: the future of treating lupus erythematosus?
Psoriatic arthritis: significant improvement with bimekizumab
Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis
Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares
Spotlight on Rheumatoid Arthritis
Comorbid depression comes with a profoundly higher mortality risk in RA
Preventive treatment with methotrexate benefits pre-RA patients with arthralgia
Risk factors for dementia in RA patients discovered
VTE in global registry data more common in JAK inhibitor-treated RA patients
Spondyloarthropathies – Novel Developments
How to treat enthesitis in 2022
Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib
Treat-to-target dose reduction effective in spondyloarthritis
A novel oral treatment possibility for non-radiographic axSpA on the horizon
Many RA and PsA patients have problems with their sex life
What Is Hot in Osteoarthritis?
New treatments in osteoarthritis
OA associated with alcohol and drug abuse
Body mass index increase associated with structural changes in knee OA
What Is New in Lupus and Scleroderma
Inhibition of Bruton’s tyrosine kinase: a new way of approaching SLE?
Pregnancies in SLE: many complications for mothers and their unborn children
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement
Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors
Best of The Posters
Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease
High prevalence of fibromyalgia in patients with inflammatory bowel disease